Elsevier launches PharmaPendium AI to cut drug approval delays with GenAI powered regulatory search and analysis.
Elsevier has introduced PharmaPendium AI, a GenAI assistant designed to speed up drug development by tackling one of the sector’s biggest hurdles: regulatory complexity. Drug approval can take years, with researchers forced to review millions of pages from the FDA and EMA. Traditional manual reviews slow submissions and expose projects to costly delays.
PharmaPendium AI addresses this by using natural language processing to turn plain-language queries into precise searches across massive regulatory datasets. Instead of hours spent digging through documents, users get citation-backed answers linked directly to FDA and EMA sources. This reduces time spent on data review by up to 66%.
The assistant is more than a search tool. It highlights potential safety signals that could block approval, summarizes past regulatory decisions, and benchmarks competitors’ submissions. This allows researchers to anticipate issues earlier, strengthen filings, and design safer trials. It also identifies opportunities to improve patient experience, extending its value beyond compliance.
Built exclusively on trusted PharmaPendium content, the system minimizes hallucinations and ensures reliability. It supports multiple languages, making it easier for international teams to collaborate. “With PharmaPendium AI, users can access critical insights quickly and apply trusted information to submissions, risk assessments, and experimental design,” said Mirit Eldor, managing director of life sciences at Elsevier.
